| Title | Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients with Different Forms of Refractory Uveitis. |
| Publication Type | Journal Article |
| Year of Publication | 2017 |
| Authors | Mackensen F, Heinz C, Jakob E, Grewing V, Lorenz H-M, Heiligenhaus A, Max R, Becker MD |
| Journal | Ocul Immunol Inflamm |
| Pagination | 1-8 |
| Date Published | 2017 Dec 29 |
| ISSN | 1744-5078 |
| Abstract | PURPOSE: TNF alpha inhibitors have revolutionized the care of vision-threatening uveitis. This study evaluated the efficacy of adalimumab (ADA) for the treatment of refractory noninfectious uveitis. DESIGN: Randomized, prospective, controlled, two-center clinical trial Methods: Patients with active uveitis despite combined oral low-dose prednisolone and immunosuppression were randomized for additional ADA with corticosteroids in a fixed tapering regime, or corticosteroids only. Primary outcome measure at three months was improved best-corrected visual acuity (BCVA; >2 lines). In case of treatment failure, switch to the other arm was possible. RESULTS: Twenty-five patients (10 ADA, 15 controls) were included. BCVA increased with ADA by > 2 lines in 6/10 patients (60%; mean increase of 0.23 logMAR), but in only 2/15 from controls (13%, mean increase of 0.04 logMAR, Fisher´s exact test p = 0.00221). CONCLUSIONS: The results show superiority of ADA over controls in severe ocular inflammation including anterior uveitis. |
| DOI | 10.1080/09273948.2017.1411518 |
| Alternate Journal | Ocul. Immunol. Inflamm. |
| PubMed ID | 29286865 |
Submitted by kej2006 on June 6, 2018 - 4:13pm